Pharmaceutical giant Eli Lilly is planning dramatically increase manufacturing in the U.S. – but it is cutting its efforts in N.J.
On Monday, the company confirmed to Fierce Pharma that it will sell its production site in Branchburg.
The move comes during a restructuring of the company’s efforts. Lilly, based in Indianapolis, is planning a $27 billion investment to bolster four other U.S. locations.
“We have a long-term plan to deliver big bets on next-gen modalities, and we are currently leading the largest manufacturing expansion in Lilly’s history,” the company told Fierce Pharma. “Following a comprehensive assessment, we are repositioning our manufacturing operations to our new facilities to optimize future flexibility for our evolving pipeline.”
Lilly announced an expansion of its manufacturing efforts in the U.S. earlier this year — an effort the company said will add 3,000 jobs.
It has not said specifically where that expansion will take place. New Jersey does not appear to be a possibility.
